title: Gatifloxacin-associated corrected QT interval prolongation, torsades de pointes, and ventricular fibrillation in patients with known risk factors.
abstract: Drugs not commonly considered to be cardioactive agents have been reported to cause prolongation of the corrected QT interval with resultant torsades de pointes or ventricular fibrillation. We report 4 cases of gatifloxacin-associated cardiac toxicity in patients with known risk factors for this adverse event.
authors.affiliation: Departments of Pharmacy Services and Medicine, Division of Clinical Pharmacology, Bassett Healthcare, Cooperstown, NY, 13326, USA. sbertino@ix.netcom.com
authors.forename: Joseph S
authors.initials: JS
authors.lastname: Bertino
authors.forename: Robert C
authors.initials: RC
authors.lastname: Owens
authors.forename: Timothy D
authors.initials: TD
authors.lastname: Carnes
authors.forename: Paul B
authors.initials: PB
authors.lastname: Iannini
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000890:Anti-Infective Agents / Q000009:adverse effects*; D005260:Female; D024841:Fluoroquinolones; D000077734:Gatifloxacin; D006321:Heart / Q000187:drug effects; D006801:Humans; D008133:Long QT Syndrome; D008875:Middle Aged; D012307:Risk Factors; D016171:Torsades de Pointes / Q000139:chemically induced*; D014693:Ventricular Fibrillation / Q000139:chemically induced*
chemical_list: D000890:Anti-Infective Agents; D024841:Fluoroquinolones; D000077734:Gatifloxacin